PTHR1 mutations associated with Ollier disease result in receptor loss of function.
暂无分享,去创建一个
M. Vikkula | B. Gérard | B. Grandchamp | A. Couvineau | C. Silve | L. Boon | G. Bertrand | C. Rouyer | Vinciane Wouters
[1] Raju Vaishya. Section Editor's Reply , 2009, Definitions.
[2] H. Xu,et al. Molecular recognition of parathyroid hormone by its G protein-coupled receptor , 2008, Proceedings of the National Academy of Sciences.
[3] J. Wit,et al. Novel mutations in the parathyroid hormone (PTH)/PTH-related peptide receptor type 1 causing Blomstrand osteochondrodysplasia types I and II. , 2007, The Journal of clinical endocrinology and metabolism.
[4] D. Casanova,et al. Les malformations veineuses: aspects cliniques et diagnostic différentiel. , 2006 .
[5] A. Cleton-Jansen,et al. Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas , 2005, The Journal of pathology.
[6] A. Cleton-Jansen,et al. Enchondromatosis (Ollier disease, Maffucci syndrome) is not caused by the PTHR1 mutation p.R150C , 2004, Human mutation.
[7] W. Mahafza. Multiple enchondromatosis Ollier's disease with two primary brain tumors. , 2004, Saudi medical journal.
[8] A. Sandberg. Genetics of chondrosarcoma and related tumors , 2004, Current opinion in oncology.
[9] R. Sciot,et al. Molecular analysis of the INK4A/INK4A‐ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression , 2004, The Journal of pathology.
[10] A. Couvineau,et al. Identification of Cytoplasmic Domains of hVPAC1 Receptor Required for Activation of Adenylyl Cyclase , 2003, Journal of Biological Chemistry.
[11] H. Kronenberg,et al. Developmental regulation of the growth plate , 2003, Nature.
[12] B. Alman,et al. Developmental Pathways in Musculoskeletal Neoplasia: Involvement of the Indian Hedgehog-Parathyroid Hormone-Related Protein Pathway , 2003, Pediatric Research.
[13] R. O’Keefe,et al. Parathyroid Hormone-Related Peptide Expression in Cartilaginous Tumors , 2002, Clinical orthopaedics and related research.
[14] P. Hogendoorn,et al. Diagnosis and prognosis of chondrosarcoma of bone , 2002, Expert review of molecular diagnostics.
[15] B. Alman,et al. A mutant PTH/PTHrP type I receptor in enchondromatosis , 2002, Nature Genetics.
[16] K. Unni,et al. Cartilaginous lesions of bone , 2001, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.
[17] A. Cleton-Jansen,et al. Up-Regulation of PTHrP and Bcl-2 Expression Characterizes the Progression of Osteochondroma towards Peripheral Chondrosarcoma and Is a Late Event in Central Chondrosarcoma , 2000, Laboratory Investigation.
[18] A. Cleton-Jansen,et al. Malignant progression in multiple enchondromatosis (Ollier's disease): an autopsy-based molecular genetic study. , 2000, Human pathology.
[19] L. Sobin,et al. World Health Organization classification of tumors , 2000, Cancer.
[20] G. de Pinieux,et al. [Chondrosarcoma secondary to multiple cartilage diseases. Study of 29 clinical cases and review of the literature]. , 1999, Revue de chirurgie orthopedique et reparatrice de l'appareil moteur.
[21] A. Cleton-Jansen,et al. Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis , 1999, The Journal of pathology.
[22] N. Amizuka,et al. Inactivating mutation in the human parathyroid hormone receptor type 1 gene in Blomstrand chondrodysplasia. , 1998, Endocrinology.
[23] A. Jobert,et al. A homozygous inactivating mutation in the parathyroid hormone/parathyroid hormone-related peptide receptor causing Blomstrand chondrodysplasia. , 1998, The Journal of clinical endocrinology and metabolism.
[24] S. Jhiang,et al. Novel, missense and loss-of-function mutations in the sodium/iodide symporter gene causing iodide transport defect in three Japanese patients. , 1998, The Journal of clinical endocrinology and metabolism.
[25] J. Roume,et al. Absence of functional receptors for parathyroid hormone and parathyroid hormone-related peptide in Blomstrand chondrodysplasia. , 1998, The Journal of clinical investigation.
[26] A. Jobert,et al. Expression of alternatively spliced isoforms of the parathyroid hormone (PTH)/PTH-related peptide receptor messenger RNA in human kidney and bone cells. , 1996, Molecular endocrinology.
[27] J. Schmidtke,et al. Pseudohypoparathyroidism type Ib is not caused by mutations in the coding exons of the human parathyroid hormone (PTH)/PTH-related peptide receptor gene. , 1995, The Journal of clinical endocrinology and metabolism.
[28] H. Jüppner,et al. A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. , 1995, Science.
[29] A. Couvineau,et al. Highly conserved aspartate 68, tryptophane 73 and glycine 109 in the N-terminal extracellular domain of the human VIP receptor are essential for its ability to bind VIP. , 1995, Biochemical and biophysical research communications.
[30] H. Jüppner,et al. Role of the extracellular regions of the parathyroid hormone (PTH)/PTH-related peptide receptor in hormone binding. , 1994, Endocrinology.
[31] H. Schwartz,et al. The malignant potential of enchondromatosis. , 1987, The Journal of bone and joint surgery. American volume.
[32] R. Vaz,et al. Ollier disease (enchondromatosis) associated with ovarian juvenile granulosa cell tumor and precocious pseudopuberty. , 1986, The Journal of pediatrics.
[33] H. Tamimi,et al. Enchondromatosis (Ollier's disease) and ovarian juvenile granulosa cell tumor. A case report and review of the literature , 1984, Cancer.
[34] Andrew K. Poznanski,et al. Les Maladies Osseuses de l'Enfant , 1975 .
[35] A. Couvineau,et al. The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics. , 2008, Molecular endocrinology.
[36] M. Vikkula,et al. [Venous malformations: clinical characteristics and differential diagnosis]. , 2006, Annales de chirurgie plastique et esthetique.
[37] P. Choong,et al. CO‐EXPRESSION OF PARATHYROID HORMONE‐RELATED PROTEIN (PTHRP) AND PTH/PTHRP RECEPTOR IN CARTILAGINOUS TUMOURS: A MARKER FOR MALIGNANCY? , 2002, Pathology.
[38] F. Mertens,et al. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone , 2002 .
[39] Cdm Fletcher,et al. World Health Organization Classification of Tumours , 2002 .
[40] M. Hentz,et al. PTHrP and Bcl-2: essential regulatory molecules in chondrocyte differentiation and chondrogenic tumors. , 1998, Verhandlungen der Deutschen Gesellschaft fur Pathologie.
[41] A. Jobert,et al. Printed in U.S.A. Copyright © 1997 by The Endocrine Society Parathyroid Hormone-Induced Calcium Release from Intracellular Stores in a Human Kidney Cell Line in the Absence of Stimulation of Cyclic Adenosine 3�,5�- , 2022 .